General
publicado em 21/11/2012 às 20h00:00
   Dê o seu voto:

ANVISA may publish new analysis on the use of sibutramine in the Brazilian market

Thereafter, the regulatory agency will decide whether to keep or not authorization for the use of slimming in the country

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



The CEO of the National Health Surveillance Agency (ANVISA), Dirceu Barbano, said on Wednesday (21), a new analysis on the use of sibutramine in the Brazilian market should be published by January 2013. Thereafter, the regulatory agency will decide whether to keep or not authorization for the use of slimming in the country.

In 2011, the agency decided to banish the slimming-based amfepramone femproporex and mazindol, called amphetamines. Already released sibutramine continued, but with restrictions. Patients and physicians must sign a liability release, which must be submitted along with the recipe at the time of purchase. Health professionals are also required to inform the Anvisa problems presented by patients.

The initial proposal was for technical agency in the country to ban the drug because international studies show that substance use increases the risk of cardiovascular problems and changes in the central nervous system. But after nine months of debate, the crew shifted and, in the last report, defended the stay of the sale and use of the medicine in Brazil. Within one year, ANVISA again analyze the maintenance of sibutramine in the Brazilian market.

The board is absolutely quiet to make any decision whether to keep sibutramine, either remove it from the market, evaluated Barbano. During breakfast with reporters, the CEO assured that information about the medication being passed by healthcare agency. She [sibutramine] can exit the market, even with all the control, we have no condition to handle the drug.

According to Anvisa, sibutramine helps lose at least 2 pounds of body weight for a period of four weeks. Treatment is indicated for those with body mass index (BMI) equal to or above 30 and not have heart disease. The maximum use of the drug is two years.

Source: AGÊNCIA BRASIL
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: ANVISA may publish new analysis on the use of sibutramine in the Brazilian market
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: ANVISA may publish new analysis on the use of sibutramine in the Brazilian market


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
sibutramine    slimming    ANVISA    the National Agency for Sanitary Vigilance    Dirceu Barbano    amfepramone femproporex    mazindol    amphetamine   
Comments:
Comment
RUTH CASSAMASSIMO
posted on:
04/01/2013 10:25:51
defendo o uso da sibutramina pois sem esse medicamento o que vamos ter para combater a obesidade o BRASIL e´um pais de obesos,naõ temos roupas com manequim de acordo com nosso biotipo,usamos remedios p hipertensaõ indiscriminadamente,fazemos cirurgias de sikicine aqui e ali e´só pagar! a anvisa deve rever os conceitos e pensar no obeso que sofre com depressaõ e outros males.o trafico vai continuar se proibir como as outras drogas que naõ consegue parar,quanto mais proibir mais riscos corremos em consumir a sibu por atravessadores doo paraguay ou de outro lugar qualquer,por favor sr diretor BARBALHO repense nessa ideia obrigado
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.